Alfred L. Garfall, MD, Abramson Cancer Center
Articles by Alfred L. Garfall, MD, Abramson Cancer Center
Multiple Myeloma: Unmet Needs and Future Directions in Care
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Combination Strategies With Bispecifics in Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Bispecifics in Multiple Myeloma: Adverse Event Management
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Factors in Selecting Therapy at First Relapse in Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
Patient Scenario: Treatment Options in MM at First Relapse
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.
Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.
Alfred L. Garfall, MD, provides insight on the FDA approval of daratumumab added to bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Patient Scenario: Treatment Options in MM at First Relapse
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy